In this study, Hopkins investigators sought to determine the time to Lupus Low Disease Activity State attainment in a group of lupus patients and identify useful predictors of achieving this low disease state.
This study from the Johns Hopkins Scleroderma Center found that scleroderma patients with multiple autoimmune responses may be protected from the development of cancer.
Alice in Wonderland may come to mind as you read this issue of LEAP, because we are moving from the large to the small, and back again: A rheumatic disease is big, and its effect can be devastating. However, a disease such as rheumatoid arthritis, scleroderma, or Sjögren’s is, in fact, multiple diseases, each slightly different.
The first thing to remember is that everybody with a diagnosis of scleroderma is at risk of developing lung disease — either interstitial lung disease (ILD), which affects about 60 […]
Summary The study shows that deep machine learning can be utilized to more accurately identify erythema migrans rashes in early Lyme disease. Recognition of the EM rash is crucial to […]
This study uses a neuroimaging radiotracer with positron emission tomography (PET) to quantify cerebral glial activation in brains of patients with post-treatment Lyme disease. Results show elevated central nervous system immune activation in patients with PTLDS as compared to controls.
